根据药明生物（股票代码：02269）于2026年11月5日发布的截至2026年10月31日止当月股份变动月报表信息，公司在报告期内就已发行股份进行更新披露。
公司本月并未对法定/注册股本进行增减变动，法定/注册股本维持在6,000,000,000股普通股不变，每股面值为0.000008333333美元，总面值为5万美元。期末已发行股份（不包括库存股）数为4,117,231,853股，相较上月底的4,116,762,450股增加了469,403股，未出现购回或注销股份的情况。
上述新发行股份主要来自公司首次公开发售前购股权计划下的行权。当月公司因购股权行权获得资金合计14.93万美元。公司于报告期内并无发生任何新的购回或库藏股变化。期末公司并无已发行且未注销之库存股份。
截至10月末，公司股本总数为4,117,231,853股，较上月小幅增加，股本结构总体稳定。公司进一步声明，已遵循香港联交所《上市规则》及相关监管规定完成本月各项股份发行及变动。公告由公司董事陈智胜签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.